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The effect of quinidine and mexiletine on the 
adaptation of ventricular refractoriness to an 
increase in rate 
The purpose of this study was to determine the effects of quinidine and mexiletine on the 
adaptation of ventricular refractoriness to a change in heart rate. The ventricular effective 
refractory period was measured at a basic drive cycle length of 500 msec with basic drive train 
durations of two beats, eight beats, 20 beats and 3 minutes. The ventricular refractory periods 
were measured in the baseline state and after oral treatment with quinidine or mexiletine in 20 
subjects each. In the baseline state, there was progressive shortening of the ventricular 
refractory period as the drive train duration increased from two beats to 3 minutes. Ouinidine 
prolonged refractoriness by 5% (p < 0.001) at each drive train duration. Mexiletine did not affect 
the ventricular effective refractory period at any of the drive train durations. In a control group of 
20 subjects, there were no significant differences between two determinations of refractoriness 
at each basic drive train duration. In conclusion, neither quinidine nor mexiletine affect the 
adaptation of ventricular refractoriness to an increase in rate. Although the ventricular effective 
refractory period measured with a conventional basic drive train duration of eight beats is often 
more than 20 msec longer than the actual ventricular effective refractory period measured with a 
drive train duration of 3 minutes, the effects of quinidine and mexiletine on the conventionally 
measured ventricular effective refractory period accurately reflect the effects of these drugs on 
the actual ventricular effective refractory period. (AM HEART J 1991;121:512.) 
Shimon Rosenheck, MD, Stephen Schmaltz, MPH, Alan H. Kadish, MD, 
Joni Summitt, DO, and Fred Morady, MD. Ann Arbor, Mich. 
Ventricular refractoriness progressively shortens 
when there is an abrupt increase in heart rate, and 
several minutes at the higher heart rate may be nec- 
essary before the maximum shortening of ventricular 
refractoriness is attained.rm8 However, in the clinical 
electrophysiology laboratory, ventricular refractori- 
ness has been conventionally measured by scanning 
diastole with an extrastimulus introduced after a ba- 
sic drive train that is only eight beats in duration,g-12 
and this method often yields a ventricular effective 
refractory period that is 10 to 30 msec longer than the 
actual ventricular effective refractory period.ls 13, l4 
In clinical electrophysiology studies, the effects of 
antiarrhythmic drugs on ventricular refractoriness 
have also been measured with a basic drive train du- 
ration of eight beats 15-lg; therefore, the effects of an- 
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tiarrhythmic drugs on the actual ventricular effective 
refractory period are not known. Depending on the 
effect of an antiarrhythmic drug on the adaptation of 
ventricular refractoriness to an increase in rate, the 
conventionally measured ventricular effective refrac- 
tory period may or may not accurately reflect the ef- 
fect of the drug on the actual ventricular effective re- 
fractory period. 
The purpose of this study was to determine the ef- 
fects of quinidine and mexiletine on the adaptation 
of ventricular refractoriness to an increase in heart 
rate. Quinidine and mexiletine were selected for this 
study because they are commonly used representa- 
tives of class IA and IB ant&rhythmic drugs.20 Our 
aim was to determine whether the effects of these 
drugs on the conventionally measured effective re- 
fractory period accurately reflect their effects on the 
actual ventricular effective refractory period. 
METHODS 
Subjects of study. The subjects of this study were 54 
patients who underwent clinically indicated electrophysi- 
ology tests for evaluation of ventricular tachycardia, unex- 
plained syncope, or paroxysmal supraventricular tachycar- 
dia. There were 48 men and 6 women, and their mean age 
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was 61 ? 12 years (+ standard deviation). Forty patients 
had coronary artery disease, six patients had cardiomyop- 
athy, and eight patients had no structural heart disease. 
The mean left ventricular ejection fraction determined by 
echocardiography or contrast or radionucleide ventricu- 
lography was 0.43 f  0.14. Thirty-four of these subjects had 
sustained monomorphic ventricular tachycardia that was 
inducible by programmed stimulation, and they underwent 
drug testing; the effects of quinidine and mexiletine were 
assessed in 20 electrophysiology tests each. An additional 
20 subjects served as a control group. Patients were not se- 
lected as subjects for this study if they were not in sinus 
rhythm at a cycle length longer than 600 msec, if ventric- 
ular tachycardia or paroxysmal supraventricular tachycar- 
dia was inducible with a single ventricular extrastimulus, 
or if 3 minutes of ventricular pacing at a cycle length of 500 
msec was not hemodynamically tolerated. 
Electrophysiology protocol. Electrophysiologic studies 
were performed in the fasting, unsedated state and after 
informed consent was obtained, either at least five half- 
lives after discontinuation of treatment with antiarrhyth- 
mic drugs or after at least 2 days of treatment with quini- 
dine or mexiletine. Two to four quadripolar electrode 
catheters (1 cm electrode spacing) were inserted into a 
femoral or subclavian vein and positioned as clinically in- 
dicated in the right atrium, His bundle position, coronary 
sinus, or right ventricle. Electrocardiographic leads VI, I, 
and III, and the intracardiac electrograms were recorded on 
a Siemens Elema Mingograph 7 recorder (Siemens Medi- 
cal Systems Inc., Iselin, N.J.) at a paper speed of 25 to 100 
mm/set. Bipolar pacing was performed with the distal pair 
of electrodes with the use of a programmable stimulator 
(Bloom Associates Ltd., Reading, Pa.). The pacing stimuli 
were 2 msec in duration and had a current strength twice 
that of the late diastolic threshold. 
Study protocol. The study protocol was approved by the 
Human Research Committee and was performed on com- 
pletion of the clinically indicated portion of the electro- 
physiology test. An electrode catheter was positioned in the 
right ventricular apex, and a stable position in which the 
pacing threshold was less than 0.8 mA was obtained with 
fluoroscopic guidance. The ventricular effective refractory 
period was measured with a pacing drive cycle length of 500 
msec and drive train durations of two beats, eight beats, 20 
beats, and 3 minutes. The 3-minute drive train was used 
because an earlier study demonstrated that this is suffi- 
cient to yield the maximum shortening of ventricular 
refractoriness when the drive train cycle length is 400 to 600 
msec.l The initial beat of the drive train was synchronized 
always to occur 500 msec after a sinus beat. I f  there was 
ventriculoatrial dissociation, the atrium was paced simul- 
taneously with the ventricle to avoid disruption of the ba- 
sic drive train by sinus capture beats. The drive trains of 
two, eight, and 20 beats were separated by an intertrain 
pause of 3 seconds. When the drive train duration was 3 
minutes, the drive train was not interrupted by pauses and 
the extrastimulus was inserted after every eighth beat of 
the drive train. 
A ventricular extrastimulus was introduced at an initial 
coupling interval that was shorter than the ventricular ef- 
fective refractory period. The coupling interval was pro- 
gressively increased in steps of 2 msec until ventricular 
capture was elicited, and the ventricular effective refrac- 
tory period was defined as the longest coupling interval 
that did not evoke a ventricular response. The ventricular 
effective refractory period was measured in this fashion 
because an earlier study demonstrated that this method 
yields a more accurate ventricular effective refractory pe- 
riod than when the extrastimulus coupling interval is ini- 
tially longer than the ventricular refractory period and the 
coupling interval is progressively shortened until ventric- 
ular capture is lost.21 
Ventricular effective refractory periods were measured 
in the control state and after at least 2 days of oral treat- 
ment with a mean of 1.4 ? 0.6 gm/day of quinidine (mean 
plasma concentration, 2.4 t 0.7 wg/ml) in 20 subjects, and 
in the control state and after at least 2 days of oral treat- 
ment with a mean of 675 ” 100 mg/day of mexiletine 
(mean plasma concentration 1.3 t 0.7 pg/ml) in 20 sub- 
jects. In six of these subjects, a single control study was 
followed by serial testing with mexiletine and quinidine, 
whereas in 28 subjects a control study was followed by a 
single drug study with either quinidine or mexiletine. 
Control group. The reproducibility of the techniques 
that were used in this study to determine the adaptation of 
ventricular refractoriness to an increase in heart rate was 
assessed in a control group of 20 subjects. In these subjects, 
ventricular effective refractory periods were measured at 
the beginning of an electrophysiology test and again 45 to 
90 minutes later, on completion of the clinically indicated 
portion of the electrophysiology test. The electrode cathe- 
ter that was used to measure the ventricular effective 
refractory periods was purposely moved out of the right 
ventricular apex and repositioned in the same general area 
before the second set of measurements to simulate the 
catheter repositioning that occurred in the subjects who 
underwent the control study and a drug study on different 
days. 
Statistics. To determine the effects of the basic drive 
train duration and the two drugs on ventricular refractori- 
ness, a repeated measures analysis of variance was used.“’ 
Multiple comparisons were performed using Fisher’s least 
significant difference multiple comparisons procedure.23 
The reproducibility of the baseline measurements of re- 
fractoriness was ascertained by calculating a reliability es- 
timate at each basic drive train duration.24 A p value of less 
than 0.05 was considered significant. 
RESULTS 
Effects of quinidine. In the baseline state in 20 sub- 
jects, the ventricular effective refractory period pro- 
gressively shortened as the basic drive train duration 
increased (Fig. 1). Quinidine significantly lengthened 
the ventricular effective refractory period at each 
basic drive train duration (Fig. 1). There were no sig- 
nificant differences in the magnitude of quinidine’s 
effects on the ventricular refractory period, either in 
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Fig. I. The effect of quinidine on the adaptation of the ventricular effective refractory period (VERP) to 
an increase in rate. Quinidine significantly lenghened refractoriness at each drive train duration (p < 0.001). 
Table I. Absolute and percent change in ventricular effec- 
tive refractory period caused by quinidine in 20 subjects 
Basic drive train duration 
Two Eight 
beats beats 20 Beats 3 Minutes 
Absolute change 29 t 21* 24 + 15* 22 k 17* 21 2 14* 
from baseline 
Percent change 11 * 4 9*3 9-+4 822 
from baseline 
Values are expressed as mean + standard deviation. 
There were no significant differences in the absolute or percent changes from 
the haseline among the various basic drive train durations. 
*p < 0.001 when compared to baseline. 
absolute terms or when expressed as percent change, 
among the different basic drive train durations (Ta- 
ble I). Quinidine did not significantly change the 
mean resting sinus cycle length (841 +- 189 msec 
baseline vs 822 -t 147 msec with quinidine). 
Effects of mexiletine. In the baseline state in 20 
subjects, the ventricular effective refractory period 
progressively shortened as the basic drive train 
duration increased, in a fashion identical to the ven- 
tricular effective refractory periods in the baseline 
studies of the subjects who were treated with quini- 
dine (Fig. 2). Mexiletine did not significantly affect 
the ventricular effective refractory period at any of 
the basic drive train durations (Fig. 2). Mexiletine 
also did not significantly affect the mean resting si- 
nus cycle length (810 -t 157 msec baseline vs 
824 & 149 msec with mexiletine). 
Control group. There were no significant differences 
between the two determinations of ventricular re- 
fractoriness at each drive train duration in the 20 
subjects in the control group (Table II). The reliabil- 
ity estimate for the measurements of refractoriness 
ranged from 0.9 for the 3-minute drive train duration 
to 0.97 for the 20-beat drive train duration. 
DISCUSSION 
Main findings. In this study, ventricular effective 
refractory periods were measured in the baseline 
state with basic drive train durations of two beats, 
eight beats, 20 beats, and 3 minutes to define the time 
course of adaptation of ventricular refractoriness to 
an increase in heart rate. As expected, the ventricu- 
lar effective refractory period was found to shorten 
progressively as the duration of the basic drive train 
increased to 3 minutes. The results of this study 
demonstrate that neither quinidine nor mexiletine 
affect the adaptation of ventricular refractoriness to 
an increase in heart rate. At a drive cycle length of 500 
msec, quinidine significantly lengthened the ventric- 
ular effective refractory period, and there was no in- 
teraction between quinidine’s effects and the dura- 
tion of the basic drive train. Mexiletine had no 
significant effect on the ventricular effective refrac- 
tory period, regardless of the duration of the basic 
drive train. Therefore although quinidine and mex- 
iletine differ in that the former prolongs ventricular 
refractoriness whereas the latter does not, both drugs 
are similar in that neither one alters the time course 
of progressive shortening in the ventricular effective 
refractory period that occurs as the duration of the 
basic drive train increases to 3 minutes. 
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Fig. 2. The’effect of mexiletine on the adaptation of the ventricular effective refractory period (VERP) 
to an increase in rate. Mexiletine had no effect on refractoriness at any of the drive train durations. 
Reproducibility of measurements. The results that 
were obtained from the 20 subjects in the control 
group demonstrated a mean difference of 1 +- 6 msec 
between two determinations of the ventricular effec- 
tive refractory period at a given basic drive train du- 
ration, and this difference was not significant. These 
findings provide validation that the lengthening of 
refractoriness that occurred during treatment with 
quinidine was in fact attributable to a drug effect and 
that a systematic drug effect was not present in the 
subjects who were treated with mexiletine. 
Use-dependent effects of quinidine and mexiletine. 
Experimental studies have demonstrated that the 
effects of antiarrhythmic drugs that block sodium 
channels such as quinidine and mexiletine, are use- 
dependent.35-2g In concert with the findings of exper- 
imental studies, clinical studies have demonstrated 
that the effects of class I antiarrhythmic drugs and 
amiodarone on His-Purkinje and intraventricular 
conduction are also use-dependent.lg, 30-32 In regard 
to the ventricular effective refractory period, exper- 
imental studies have demonstrated that class I drugs, 
including quinidine and mexiletine, have frequency- 
dependent effects on the ventricular effective refrac- 
tory period,27> 33, 34 and an earlier clinical study dem- 
onstrated that procainamide has use-dependent ef- 
fects on ventricular refractoriness.35 However, no 
previous clinical studies have investigated the use- 
dependent effects of quinidine or mexiletine on the 
ventricular effective refractory period. Depending on 
the binding and dissociation kinetics of these drugs, 
effects on the ventricular effective refractory period 
might be expected to be less pronounced after a drive 
train of two beats than after drive trains of eight 
beats or more. However, because pacing was per- 
formed only at a single cycle length of 500 msec, no 
Table II. Two determinations of the ventricular effective 
refractory period in 20 control subjects 
Basic drive train duration 
Two Eight 
beats beats 20 Beats 3 Minutes 
First determination 264-t26 253i24* 244?22* 227zk13” 
Second determination 264 f 26 253 + 24* 245 f 23* 229 k 15* 
Values are expressed as mean i- standard deviation. 
There were no significant differences between the two determinations of re- 
fractoriness at any of the drive train durations. 
*p < 0.001 when compared to preceding drive train duration. 
conclusions can be drawn in regard to the presence or 
absence of use-dependent effects of quinidine or 
mexiletine on ventricular refractoriness. 
Limitations. A limitation of this study is that the 
adaptation of ventricular refractoriness to an in- 
crease in heart rate was determined with only a sin- 
gle pacing cycle length of 500 msec. The results that 
were obtained at this cycle length may not be appli- 
cable to other cycle lengths. A second limitation is 
that serial measurements of the ventricular effective 
refractory period in the control group were obtained 
in the course of a single electrophysiology test, and 
day-to-day variability in the measurement of the 
ventricular effective refractory period therefore was 
not controlled. The third limitation is that the use of 
a 3-second intertrain pause when the ventricular ef- 
fective refractory period was measured may have al- 
lowed for a cumulative effect of the basic drive trains 
on the ventricular effective refractory periods; there- 
fore, the ventricular effective refractory periods that 
were measured during basic drive trains of two, eight, 
and 20 beats may have been influenced not only by 
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the number of beats in the drive train but also by the 
total number of drive trains that preceded the 
particular drive train that defined the ventricular ef- 
fective refractory period. Finally, we cannot rule out 
the possibility that higher plasma drug concentra- 
tions than those tested in this study would have 
yielded different results. 
Conclusions. Because ventricular refractoriness 
adapts to an increase in heart rate in a gradual fash- 
ion, the conventional method of determining the 
ventricular effective refractory period with a basic 
drive train of eight beats does not yield an accurate 
measurement of the actual ventricular effective re- 
fractory period. When the basic drive train cycle 
length is 500 msec, the conventionally measured 
ventricular effective refractory period overestimates 
the actual ventricular effective refractory period by a 
mean of more than 20 msec. Nevertheless, because 
neither quinidine nor mexiletine affects the adapta- 
tion of ventricular refractoriness to an increase in 
heart rate, the effects of these drugs on the conven- 
tionally measured ventricular effective refractory 
period are similar in magnitude to their effects on the 
actual ventricular effective refractory period. There- 
fore although conventional measurements of ventric- 
ular refractoriness are inaccurate in absolute terms, 
the change in ventricular effective refractory period 
that results from treatment with quinidine or mexi- 
letine can be accurately determined regardless of the 
duration of the basic drive train, at least when the 
cycle length of the basic drive train is 500 msec. 
The authors are grateful to Deanne Backhaus and Marion 









Morady F, Kadish AH, Toivonen LK, Kushner JA, Schmaltz 
S. The maximum effect of an increase in rate on human ven- 
tricular refractoriness. PACE 1988;11:2223-34. 
Gibbs CL, Johnson EA. Effect of change in frequency of stim- 
ulation upon rabbit ventricular action potential. Circ Res 
1961;9:165-70. 
Janse MJ, van der Steen ABM, van Dam RTh, Durrer D. Re- 
fractory period of the dog’s ventricular myocardium following 
sudden change in frequency. Circ Res 1969;24:251-62. 
Vick RL. Action potential duration in canine Purkinje tissue: 
effects of preceding excitation. J Electrocardiol1971;4:IO5-15. 
Miller JP, Wallace AG, Feezor MD. A quantitative compari- 
son of the relation between the shape of action potential and 
the pattern of stimulation in canine ventricular muscle and 
Purkinie fibers. J Moll Cell Cardiol 1971:2:3-19. 
BoyettMR. An analysis of the effect of the rate of stimulation 
and adrenaline on the duration of the cardiac action potential. 
Pfluger Archiv 1978;377:155-66. 
Lab MJ, Yardley J. Electrophysiological differences between 
apex and base in intact pig ventricle. J Physiol 1979;292:62P- 
63P. 









and rhythm upon electrical activity in the heart. Prog Biophys 
Mol Biol 1980;36:1-52. 
Cooper MJ, Koo CC, Skinner MP, Mortensen PT, Hunt LJ, 
Richards DA, Uther JB, Ross DL. Comparison of immediate 
versus day by day variability of ventricular tachycardia 
induction by programmed stimulation. J Am Co11 Cardiol 
1989;13:1599-607. 
Vassal0 JA, Marchlinski FE, Cassidy DM, Buxton AE, Jo- 
sephson ME. Shortening of ventricular refractoriness with ex- 
trastimuli: role of the degree of prematurity and number of 
extrastimuli. J Electrophysiol 1988;2:227-36. 
Estes III NAM, Garan H, McGovern B, Ruskin JN. Influence 
of drive cycle length during programmed stimulation on the 
induction of ventricular arrhythmias: analysis of 403 patients. 
Am J Cardiol 1986;57:108-12. 
Morady F, Kou WH, Kadish AH, Kadish AH, Schmaltz S, 
Summitt J, Rosenheck S. Effect of basic train cycle length on 
induction of ventricular tachycardia by a single extrastimulus. 
J Electrophysiol 1989;3:111-16. 
Prystowsky EN, Miles WN. Human ventricular refractoriness: 
Interdependency of drive train duration, current strength and 
heart rate [abstract]. J Am Co11 Cardiol 1984;3:537. 
Brownstein SL, Buaernfeind R, Welsh W, Blackwell W, Con- 
stantin L. Cumulative effect of cycle length on ventricular re- 
fractoriness in man [abstract]. PACE 1987;10:432. 
DiMarco JP, Garan H, Ruskin JN. Quinidine for ventricular 
arrhythmias: value of electrophysiologic testing. Am J Cardiol 
1983;51:90-5. 
Morady F, Kou WH, Kadish AH, Nelson SD, Toivonen LK, 
Kushner JA, Schmaltz S, deBuitler M. Antagonism of quini- 
dine’s electrophysiologic effects by epinephrine in patients 









Morady F, DiCarlo LA, deBuitleir M, Krol RB, Baerman JM. 
Effect of incremental dose of procainamide on ventricular re- 
fractoriness, intraventricular conduction, and induction of 
ventricular tachycardia. Circulation 1986;74:1355-64. 
Rinkenberger RL, Pristowski EN, Jackman WM, Nacarelli 
GV, Heger JJ, Zipes DP. Drug conversion of nonsustained 
ventricular tachycardia during serial electrophysiologic 
studies: identification of drugs that exacerbate tachvcardia 
and potential mechanisms. Ab HEART J 1982;103:171-84. 
Marchlinski FE, Buxton AE, Kindwall E, Miller JM, Rosenthal 
ME, Gottlieb CD, Blood RB, Josephson ME. Comparison of 
individual and combined effect of procainamide and amio- 
darone in patients with sustained ventricular tachycardia. 
Circulation 1988:78:583-91. 
Vaugham Williams EM. A classification of antiarrhythmic ac- 
tion reassessed after a decade of new drugs. J Clin Pharmacol 
1984;24:129-47. 
Morady F, Kadish AH, Kushner JA, Toivonen LK, Schmaltz 
S. Comparison of ventricular refractory periods determined by 
incremental and decremental scanning of an extrastimulus. 
PACE 1989;12:546-54. 
Berk K. Computing for incomplete repeated measured. Bio- 
metrics 1987;43:385-98. 
Milliken GA, Johnson DE. Analysis of messy data. Volume I: 





Winer DG. Statistical principles in experimental design. New 
York: McGraw Hill Book Co.. 1971:283-96. 
Hondeghem L, Katzung BG. Test of a model of anti arrhyth- 
mic drug action: effect of quinidine and lidocaine on myocar- 
dial conduction. Circulation 1980;61:1217-24. 
Shen X, Antzelevitch C. Mechanisms underlying the antiar- 
rhythmic and arrhythmogenic action of quinidine in a Pukinje 
Fiber-ischemic gap preparation of reflected reentry. Circu- 
lation 1986;73:1342-53. 
27. Roden DM, Iansmith DHS, Woosley RL. Frequency-depen- 
Volume 121 
Number 2, Part 1 Quinidine and mexiletine on ventricular refractoriness 
dent interactions of mexiletine and quinidine on depolariza- 
tion and repolarization in canine Purkinje Fibers. J Pharma- 
co1 Exp Ther 1987;243:1218-24. 
28. Clarkson CW, Hondeghem LC. Evidence for a specific recep- 
tor site for lidocaine, quinidine, and bipivacaine associated 
with cardiac sodium channels in guinea pig ventricular myo- 
cardium. Circ Res 1985;56:496-506. 
29. Bajaj AK, Kopelman HA, Wikswo JP, Cassidy F, Kopelman 
HA, Woosey RL, Roden DM. Frequency- and orientation-de- 
pendent effect of mexiletine and quinidine on the conduction 
in the intact dog heart. Circulation 1987;75:1065-73. 
30. Mercer AB, Foster JR, Simpson RJ Jr, Bettes LS. Use-depen- 
dency of antiarrhythmic drugs in the human heart [abstract]. 
Circulation 1983;68 (suppl III):III-286. 
31. Morady F, DiCarlo L Jr, Baerman J, Krol RB. Rate-dependent 
effect of lidocaine, procainamide and amiodarone on intra- 
ventricular conduction. J Am Co11 Cardiol 1985;6:179-85. 
32. Gang ES, Denton TA, Oseran DS, Mandel WJ, Peter T. Rate- 
dependent effect of procainamide on His-Purkinje conduction 
in man. 1985;55:1525-9. 
33. Nattel S, Zeng FD. Frequency-dependent effects of antiar- 
rhythmic drugs on action potential duration and refractori- 
ness of canine cardiac Purkinje fibers. J Pharmacol Exp Ther 
1984;229:283-91. 
34. Franz MR, Costard A. Frequency-dependent effect of quini- 
dine on the relationship between action potential duration and 
refractoriness in the canine heart in situ. Circulation 1988; 
7711177-84. 
35. Marchlinski FE, Shinnar M. Cycle length dependent effect of 
procainamide on ventricular refractoriness [abstract]. J Am 
Co11 Cardiol 1987;9:227A. 
Effect of hyperkalemia on experimental 
myocardial depression by verapamil 
Three patients with systemic hypotension and sinus bradycardia that were initially refractory to 
conventional therapy responded well to intravenous calcium administration. Two-dimensional 
echocardiography revealed immediate reversal of severe left ventricular dysfunction after 
intravenous administration of calcium in two instances. Common factors were hyperkalemia and 
verapamil therapy. This interaction was examined further by evaluation of contractility, heart rate, 
and arterial blood pressure in anesthetized dogs. Controls (n = 9) received saline infusion, and a 
second group (n = 10) received saturated potassium chloride (approximately 0.2 ml/min 
intravenously). In control dogs, administration of verapamil (1195 & 181 fig/kg intravenously) 
reduced systemic arterial pressure from 113 + 7 mm Hg to 74 + 5 mm Hg, and heart rate from 
147 rt 9 beats/min to 86 i 11 beats/min. Potassium chloride infusion alone increased blood 
[K+] from 3.4 * 0.1 to 6.2 + 0.2 mEq/L, but was without hemodynamic effects. In hyperkalemic 
dogs, a significantly lower dose of verapamil (428 +- 42 pg/kg intravenously) reduced systemic 
arterial pressure from 102 +- 8 mm Hg to 36 +- 4 mm Hg, and heart rate from 150 _+ 5 beats/min 
to 104 f 15 beats/min. Myocardial contractile function was examined with right ventricular 
isometric contractile force and left ventricular segment length changes. In normokalemic and 
hyperkalemic groups, contractility was decreased by verapamil. Effects of verapamil on arterial 
pressure and contractility could be reversed significantly by administration of calcium, 0.4 
mEq/kg intravenously. The present results support the theory that the negative hemodynamic 
effects of verapamil may be exaggerated to a harmful degree by concomitant hyperkalemia. 
These adverse events may be reversed by calcium administration. (AM HEART J 1991;121:517.) 
Stanley R. Jolly, PhD, Nancy Keaton, MD, Assad Movahed, MD, 
Gregory C. Rose, MD, and William C. Reeves, MD. GreenuiZZe, N.C. 
Verapamill-” is one of the first calcium channel 
blockers to be used clinically for the treatment of 
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systemic hypertension, supraventricular tachyar- 
rhythmias, and angiha pectoris. High doses of ver- 
apamil can produce significant myocardial depres- 
sion with reduced ventricular contractility, sinus 
bradycardia, atrioventricular conduction delay, and 
systemic hypotension. 4, 5 Clinical and experimental 
studies have suggested when adverse exaggerated re- 
sponses to verapamil could be expected to occur. For 
example, intravenous verapamil plus /3-adrenergic 
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